- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06076980
Heamodynamic Effects of Paracetamol in Septic Shock Patients
Haemodynamic Effects of Paracetamol (Acetaminophen) as Extended Intravenous Infusion Versus Intravenous Bolus in Septic Shock Patients
Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. Septic shock is defined as sepsis that has circulatory, cellular, and metabolic abnormalities that are associated with a greater risk of mortality than sepsis alone. Clinically, this includes patients who fulfill the criteria for sepsis who, despite adequate fluid resuscitation, require vasopressors to maintain a mean arterial pressure ≥65 mmHg and have a lactate >2 mmol/L (>18 mg/dL). Feve is a common sign of infection in septic shock critically ill patients. Many critically ill patients experience pain. Paracetamol is considered safe and currently one of the most common antipyretics and used as part of multimodal analgesia for acute pain in the intensive care unit. According to the company's product information leaflet, the rate of hypotension complicating intravenous paracetamol treatment ranges from 0.01 to 0.1%. However, recent studies reported a much higher incidence and may be harmful in critically ill adults. The hemodynamic effects of intravenous (IV) paracetamol are unknown in septic shock patients, that the most vulnerable population and hemodynamically unstable.
The aim of this study is to assess the incidence of hypotension of the extended intravenous paracetamol (acetaminophen) infusion over three hours in comparing with intravenous paracetamol bolus over 15 minutes in hemodynamically unstable patients (septic shock).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sepsis, inflammatory response to infection, contributes directly or indirectly to mortality in the majority of critically ill patients. An elevated cardiac index and a decreased systemic vascular resistance leading to hypotension and hypoperfusion of vital organs characterize the early stage of septic shock. The hypotensive state is often not amenable to fluid resuscitation alone and requires institution of vasoactive agents to counter the profound fall in systemic vascular resistance, which is an integral feature of septic shock .
Acetaminophen is the antipyretic and analgesic that is most often given to hospitalized patients, including those in critical care units. The mechanism of action of acetaminophen remains incompletely understood, but the antipyretic response appears to be due to blocking cyclooxygenase-II and inhibiting prostaglandin-II synthesis in the central nervous system.
Intravenous (IV) acetaminophen has gained popularity for inpatient management of acute pain for its practical and clinical advantages. IV administration is associated with more predictable pharmacokinetic performance compared with rectal (30%-40% bioavailability) and oral dosage forms of acetaminophen (60%-70% bioavailability).
Predictable kinetics as well as ease of IV administration has made it an especially attractive option in the critically ill patients who have altered gut absorption secondary to numerous pathophysiological and therapeutic influences .
IV acetaminophen has shown promise in improving patient satisfaction, managing fever, and decreasing postoperative opioid requirements. These features have made it one of the most widely ordered medications within critical care and surgical services.
Product information for IV acetaminophen lists mild effects such as nausea or vomiting among the most common adverse events (incidence ≥ 5%), with the estimated incidence of more serious adverse effects such as hypotension being <1%. However, there have been an increasing number of randomized controlled trials which indicated that the incidence of IV acetaminophen-induced hypotension may be higher than previously reported by manufacturers. These publications have prompted investigators to look more closely at the possible untoward effects of IV acetaminophen across a variety of populations. . None of these studies examined whether the extended infusion of IV paracetamol can minimize the degree of hypotension in critically heamodynamic unstable patients.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt, 11725
- Cairo University Hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age adult ≥ 18 years old.
The patient fulfills the criteria of septic shock definition:
- Sepsis needs vasopressor therapy.
- Serum lactate level greater than 2 mmol/l (SSC 2016).
- Patient with contractility greater than 40%
Exclusion Criteria:
- paracetamol hypersensitivity or allergy.
- Acute liver injury or failure
- Childs-Pugh C liver disease
- Heat stroke.
- Malignant hyperthermia.
- Neuroleptic Malignant Syndrome.
- Continous renal replacement therapy.
- Ventricular assist device.
- Around-the-clock scheduled of acetaminophen-containing medications administration or non-steroidal anti-inflammatory drugs.
- Pregnancy/lactation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo group
placebo group (100 ml normal saline over 15 minutes)
|
as placebo
|
Experimental: bolus group
bolus group (1000mg/100 ml paracetamol over 15 minutes)
|
compare the hemodynamic parameters of paracetamol as bolus versus extended infusion
Other Names:
|
Experimental: Extended infusion group
Extended infusion (1000mg/100 ml paracetamol over 3 hours)
|
compare the hemodynamic parameters of paracetamol as bolus versus extended infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of hypotension .
Time Frame: pre intervention and six hours after the intervantion
|
defined as a decrease in SBP ≥ 20٪ from baseline, by extended infusion of intravenous paracetamol
|
pre intervention and six hours after the intervantion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The changes in hemodynamic parameters
Time Frame: pre intervention and six hours after the intervantion
|
Changes in cardiac output ( L/min)
|
pre intervention and six hours after the intervantion
|
The changes in hemodynamic parameters
Time Frame: pre intervention and six hours after the intervantion
|
Changes in heart rate (bpm)
|
pre intervention and six hours after the intervantion
|
The changes in hemodynamic parameters
Time Frame: pre intervention and six hours after the intervantion
|
Changes in central venous pressure (mmHg)
|
pre intervention and six hours after the intervantion
|
The changes in temperature
Time Frame: pre intervention and six hours after the intervantion
|
Changes in temperature (celsius)
|
pre intervention and six hours after the intervantion
|
The changes in vassopresors and fluid bolus
Time Frame: pre intervention and six hours after the intervantion
|
changes in vassopresors infusion rate (mcg/ min) and fluid bolus
|
pre intervention and six hours after the intervantion
|
The changes in hemodynamic parameters
Time Frame: pre intervention and six hours after the intervantion
|
Changes in mean arterial pressure(mmHg), diastolic blood pressure (mmHg)
|
pre intervention and six hours after the intervantion
|
The changes in vassopresors and fluid bolus
Time Frame: pre intervention and six hours after the intervantion
|
changes in fluid bolus (ml)
|
pre intervention and six hours after the intervantion
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- paracetamol in septic shock
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
-
Inverness Medical InnovationsCompletedSepsis | Systemic Inflammatory Response Syndrome | Severe Sepsis | Sepsis SyndromeUnited States
Clinical Trials on Normal saline
-
Texas Cardiac Arrhythmia Research FoundationSuspendedVentricular ArrythmiaUnited States
-
The Catholic University of KoreaCompleted
-
Ann & Robert H Lurie Children's Hospital of ChicagoWithdrawn
-
Texas Cardiac Arrhythmia Research FoundationCompleted
-
MemorialCare Health SystemCompletedLength of Labor | Second Stage of Labor | Intravenous Hydration of LaborUnited States
-
University of HaifaWestern Galilee Hospital-NahariyaRecruiting
-
McMaster UniversityGlaxoSmithKline; University of ManchesterRecruitingAsthma | Eosinophilic Bronchitis | Chronic CoughCanada
-
University of MichiganRadiological Society of North AmericaTerminated
-
Virginia Commonwealth UniversityUnited States Department of DefenseWithdrawn
-
Qassim UniversityCompletedApical Periodontitis | Post Operative Pain | Dental Pulp NecrosesSaudi Arabia